Molecular Partners Ag (MOLN) Receivables (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Receivables of $2953.7 for Q1 2026, down 33.23% year-over-year from $4423.4 in Q1 2025, and down 97.15% quarter-over-quarter from $103639.4 in Q4 2025.
Molecular Partners Ag (MOLN) Receivables (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Receivables for 7 consecutive years, with $2953.7 the latest figure, recorded in Q1 2026.
- In Q1 2026, Receivables fell 33.23% year-over-year to $2953.7; the TTM figure through Mar 2026 stood at $2953.7 (down 33.23% YoY), while the FY2025 annual figure was $2.4 million, down 12.32% from the prior year.
- Receivables eased to $2953.7 in Q1 2026 per MOLN's latest filing, from $103639.4 in the prior quarter.
- Across five years, Receivables topped out at $20.7 million in Q2 2023 and bottomed at $1791.3 in Q3 2022.
- Historically, Receivables has averaged $3.9 million across 5 years, with a median of $4354.4 in 2025.
- Annual changes were most pronounced in 2023 — Receivables jumped 100.43% — and 2025, when it tumbled 99.98%.
- Molecular Partners Ag's Receivables stood at $1.1 million in 2022, then surged by 100.43% to $2.3 million in 2023, then advanced by 20.06% to $2.7 million in 2024, then plunged by 96.21% to $103639.4 in 2025, then slumped by 97.15% to $2953.7 in 2026.
- Business Quant data shows MOLN's Receivables at $2953.7 in Q1 2026, $103639.4 in Q4 2025, and $2629.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.90 Bn | 131.05 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.11 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 65.56 Bn | 60.37 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 55.82 Bn | 50.68 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 42.14 Bn | 37.04 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 912.74 Mn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | 1.09 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 215.33 Mn |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | - |
| 10 | Molecular Partners Ag | 163.99 Mn | 163.99 Mn | - | 2,953.71 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2,953.71 |
| Dec 31, 2025 | 103,639.40 |
| Sep 30, 2025 | 2,628.98 |
| Jun 30, 2025 | 4,354.44 |
| Mar 31, 2025 | 4,423.42 |
| Dec 31, 2024 | 2.73 Mn |
| Sep 30, 2024 | 3,829.66 |
| Jun 30, 2024 | 20.57 Mn |
| Mar 31, 2024 | 3,642.12 |
| Dec 31, 2023 | 2.28 Mn |
| Sep 30, 2023 | 2,022.02 |
| Jun 30, 2023 | 20.69 Mn |
| Mar 31, 2023 | 1,885.55 |
| Dec 31, 2022 | 1.14 Mn |
| Sep 30, 2022 | 1,791.34 |
| Jun 30, 2022 | 19.31 Mn |
| Mar 31, 2022 | 3,761.68 |
| Dec 31, 2021 | 27.98 Mn |
| Sep 30, 2021 | 6,079.52 |
| Dec 31, 2020 | 4.36 Mn |